A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the effect of moderate liver impairment on the pharmacokinetics
of saquinavir and ritonavir at steady state following administration of saquinavir/ritonavir
1000mg/100mg po bid in HIV patients. Saquinavir/ritonavir will be administered concomitantly
with 2 to 3 active nucleoside reverse transcriptase inhibitors. The study will compare a
group of HIV patients without known liver disease and a group with moderate liver disease.
The anticipated time on study treatment is <3 months, and the target sample size is <100
individuals.